logoLANDING BIOTECH INC

Fax: 617-964-1187

EMAIL: sales@landingbiotech.com



HUMAN UROKINASE AMINO-TERMINAL FRAGMENT (II)


Other Product Description
VEGF-165
Aprotinin
Urokinase
Prourokinase Non-glycosylated
Prourokinase Glycosylated
ATF
ATF II
Tissue Plasminogen
Activator

Glu-plasminogen
Lys-plasminogen
Plasmin
ETI

rEK

K2tPA

 

 

DESCRIPTION:
Amino-terminal fragment ( ATF-II, amino acid 1-135 ) was produced from pro-urokinase employing controlled Kellikrein digestion, followed by autolysis. Unlike ATF which is a single chain peptide fragment, the peptide bond between K23 and Y24 in growth factor domain (GFD) was cleaved in ATF-II, which was confirmed by N-terminal sequence analyzed with a PE/BD Procise 494 HT Protein Sequencing System. ATF-II is unable to bind to u-PA receptor (u-PAR) and has no effect on monocyte adhesion. Compared with ATF, ATF-II has a looser conformation. The molecular weight of ATF-II is about 15,000 dalton.

SOURCE:
Recombinant Pro-urokinase

PURITY:
Greater than 95% by SDS-PAGE.

ACTIVITY:
ATF-II is unable to bind to u-PAR and has no effect on monocyte adhesion.

PRESENTATION:
White lyophilized powder or solution.

STORAGE:
The lyophilized powder is best stored desiccated below 0 C. After it is reconstituted with sterile water or other buffered solutions, it should be stored at -20 C.


|Main Page |Top of the Page | Send us an Email |